Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 20,000 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the transaction, the chief financial officer owned 123,269 shares in the company, valued at approximately $20,749,870.77. The trade was a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jack Anders also recently made the following trade(s):

• On Tuesday, June 16th, Jack Anders sold 2,722 shares of Revolution Medicines stock. The shares were sold at an average price of $156.12, for a total value of $424,958.64.

Revolution Medicines Price Performance

RVMD opened at $182.08 on Friday. The firm has a market capitalization of $38.71 billion, a P/E ratio of -25.75 and a beta of 1.40. The stock has a fifty day moving average of $151.78 and a 200-day moving average of $116.68. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a 12-month low of $34.00 and a 12-month high of $184.39.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the previous year, the business earned ($1.13) earnings per share. Equities analysts forecast that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock worth $1,331,739,000 after purchasing an additional 1,056,792 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Revolution Medicines by 194.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock valued at $1,696,000 after purchasing an additional 14,062 shares during the period. Mass General Brigham Inc bought a new stake in shares of Revolution Medicines in the fourth quarter valued at approximately $27,407,000. M&T Bank Corp bought a new stake in Revolution Medicines in the 4th quarter valued at $52,723,000. Finally, Eagle Health Investments LP bought a new stake in Revolution Medicines in the 4th quarter valued at $9,231,000. Institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on RVMD. Oppenheimer increased their price target on shares of Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a research report on Monday, June 1st. UBS Group initiated coverage on shares of Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Royal Bank Of Canada increased their target price on shares of Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Sanford C. Bernstein began coverage on shares of Revolution Medicines in a research note on Thursday, May 21st. They set a “market perform” rating and a $151.00 target price for the company. Finally, Wedbush restated an “outperform” rating on shares of Revolution Medicines in a report on Monday, June 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $123.72.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.